A 28-year-old woman with Graves' disease has been on methimazole 20 mg daily for 6 weeks and is now euthyroid (TSH 1.2 mIU/L, free T4 12 pmol/L). She is keen to avoid radioactive iodine and surgery. She asks about long-term management options. What is the most appropriate next step?

Explanation

## Clinical Context **Key Point:** The patient has achieved euthyroid state on methimazole and wishes to pursue medical (non-ablative) therapy. The next step is to transition to a long-term maintenance regimen that minimizes relapse risk and side effects. ## Long-Term Antithyroid Drug Strategies ### Two Approaches to Maintenance Therapy | Strategy | Titration Regimen | Block-and-Replace Regimen | |----------|-------------------|---------------------------| | **Mechanism** | Reduce ATD dose as TSH normalizes | Fixed ATD dose + fixed levothyroxine | | **ATD dose** | Start high, taper down | Lower fixed dose (e.g., 5–10 mg) | | **Levothyroxine** | None | Added to prevent hypothyroidism | | **Monitoring** | Frequent (every 4–6 weeks initially) | Less frequent (every 8–12 weeks) | | **Relapse rate** | 30–50% after 12–18 months | Similar, but better compliance | | **Advantages** | Lower total drug exposure | Stable TSH, fewer dose adjustments | | **Disadvantages** | More frequent monitoring, more adjustments | Requires two drugs | | **First-line in most guidelines** | ✓ Standard approach | ✓ Equally acceptable | **High-Yield:** Both titration and block-and-replace are acceptable long-term strategies. Block-and-replace is preferred when: - Patient compliance is a concern - Frequent monitoring is difficult - Fluctuating TSH causes symptoms - Patient preference for stable dosing ### Block-and-Replace Regimen Details **Clinical Pearl:** The block-and-replace approach uses a fixed, lower dose of antithyroid drug (5–10 mg methimazole or 50–100 mg PTU) combined with a fixed dose of levothyroxine (25–50 mcg). This maintains stable free T4 and TSH, reducing the need for frequent dose adjustments. 1. **Reduce methimazole** from 20 mg to 5 mg daily (lower dose reduces agranulocytosis risk from ~0.3% to ~0.01%) 2. **Add levothyroxine 25 mcg** to prevent hypothyroidism as methimazole suppresses thyroid function 3. **Monitor TSH** every 8–12 weeks; adjust both drugs together if needed 4. **Target TSH** 0.5–2.5 mIU/L (slightly suppressed to reduce relapse) 5. **Duration** 12–24 months; reassess for remission (test after stopping both drugs) ```mermaid flowchart TD A[Euthyroid on ATD<br/>TSH normalized]:::outcome --> B{Long-term strategy?}:::decision B -->|Titration regimen| C[Reduce ATD dose gradually<br/>Monitor TSH every 4-6 weeks]:::action B -->|Block-and-replace| D[Reduce ATD to 5-10 mg<br/>Add levothyroxine 25-50 mcg]:::action C --> E[Achieve minimal ATD dose<br/>or discontinue]:::action D --> F[Monitor TSH every 8-12 weeks<br/>Adjust both drugs together]:::action E --> G{Remission?}:::decision F --> G G -->|Yes| H[Discontinue ATD<br/>Continue levothyroxine if needed]:::action G -->|No| I[Restart ATD or consider<br/>RAI/surgery]:::action ``` ### Remission Criteria **Key Point:** After 12–24 months of antithyroid therapy, attempt to assess for remission by: 1. Stopping both ATD and levothyroxine (if using block-and-replace) 2. Rechecking TSH and free T4 after 4–6 weeks 3. If TSH and free T4 normal → remission achieved; continue observation 4. If TSH suppressed or free T4 elevated → relapse; restart therapy or pursue RAI/surgery **Remission rates:** ~30–50% after 12–18 months of antithyroid therapy; higher in patients with smaller goitres and lower initial free T4. ## Why Block-and-Replace Is Chosen Here 1. **Stable TSH** reduces fluctuating symptoms and need for frequent adjustments 2. **Lower ATD dose** (5 mg vs. 20 mg) significantly reduces agranulocytosis risk 3. **Predictable thyroid hormone levels** improve patient compliance and satisfaction 4. **Standard long-term approach** recommended by endocrinology guidelines for medical therapy 5. **Allows reassessment** for remission after 12–24 months by stopping both drugs